Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria

  • Gonzalez, Mark D. (Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine) ;
  • McMullen, Allison R. (Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine) ;
  • Wallace, Meghan A. (Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine) ;
  • Crotty, Matthew P. (Pharmacy Department, Barnes-Jewish Hospital) ;
  • Ritchie, David J. (Pharmacy Department, Barnes-Jewish Hospital) ;
  • Burnham, Carey-Ann D. (Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine)
  • Received : 2016.03.14
  • Accepted : 2016.11.17
  • Published : 2017.03.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Estabrook M, Bussell B, Clugston SL, Bush K. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum $\beta$-lactamases. J Clin Microbiol 2014;52:4049-52. https://doi.org/10.1128/JCM.02357-14
  2. Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother 2015;59:3656-9. https://doi.org/10.1128/AAC.05024-14
  3. Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 2016;60:3227-31. https://doi.org/10.1128/AAC.02969-15
  4. Doern CD, Dunne WM Jr, Burnham CA. Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods. J Clin Microbiol 2011;49:1143-7. https://doi.org/10.1128/JCM.02163-10
  5. Centers for Disease Control and Prevention, Multiplex real-time PCR detection of Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-$\beta$-lactamase (NDM-1). http://www.cdc.gov/hai/pdfs/labsettings/kpc-ndm-protocol-2011.pdf. 2010.
  6. Manji R, Bythrow M, Branda JA, Burnham CA, Ferraro MJ, Garner OB, et al. Multi-center evaluation of the $Vitek^{(R)}$ MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2014;33:337-46. https://doi.org/10.1007/s10096-013-1961-2
  7. Richter SS, Sercia L, Branda JA, Burnham CA, Bythrow M, Ferraro MJ, et al. Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the Vitek MS system. Eur J Clin Microbiol Infect Dis 2013;32:1571-8. https://doi.org/10.1007/s10096-013-1912-y
  8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 25th Informational supplement, M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute, 2015.
  9. Sucher AJ, Chahine EB, Cogan P, Fete M. Ceftolozane/tazobactam: A new cephalosporin and $\beta$-lactamase inhibitor combination. Ann Pharmacother 2015;49:1046-56. https://doi.org/10.1177/1060028015593293

Cited by

  1. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds vol.61, pp.10, 2017, https://doi.org/10.1128/aac.00875-17
  2. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates vol.61, pp.12, 2017, https://doi.org/10.1128/aac.01858-17
  3. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa vol.56, pp.9, 2017, https://doi.org/10.1128/jcm.00717-18
  4. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar vol.74, pp.12, 2017, https://doi.org/10.1093/jac/dkz379
  5. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary vol.67, pp.1, 2017, https://doi.org/10.1556/030.2020.01152
  6. Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective vol.8, pp.None, 2021, https://doi.org/10.3389/fmed.2021.617378
  7. New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam vol.65, pp.7, 2021, https://doi.org/10.1128/aac.02318-20
  8. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resist vol.9, pp.1, 2017, https://doi.org/10.1128/spectrum.00585-21